Roidl A - Search Results

1

Downregulation of GRK5 hampers the migration of breast cancer cells.

Sommer AK, Falcenberg M, Ljepoja B, Fröhlich T, Arnold GJ, Wagner E, Roidl A. Sommer AK, et al. Among authors: roidl a. Sci Rep. 2019 Oct 29;9(1):15548. doi: 10.1038/s41598-019-51923-1. Sci Rep. 2019. PMID: 31664083 Free PMC article.

2

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.

Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Oak PS, et al. Among authors: roidl a. Int J Cancer. 2012 Dec 15;131(12):2808-19. doi: 10.1002/ijc.27595. Epub 2012 May 21. Int J Cancer. 2012. PMID: 22511343

3

miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.

Kopp F, Oak PS, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. PLoS One. 2012;7(11):e50469. doi: 10.1371/journal.pone.0050469. Epub 2012 Nov 29. PLoS One. 2012. PMID: 23209748 Free PMC article.

4

A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy.

Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, Wagner E. Kubisch R, et al. Among authors: roidl a. Transl Oncol. 2013 Feb;6(1):1-9. doi: 10.1593/tlo.12295. Epub 2013 Feb 1. Transl Oncol. 2013. PMID: 23418611 Free PMC article.

5

De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells.

Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A, Ogris M. Kopp F, et al. Among authors: roidl a. Gene Ther. 2013 Nov;20(11):1104-9. doi: 10.1038/gt.2013.37. Epub 2013 Jun 27. Gene Ther. 2013. PMID: 23804075

6

V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.

Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E. Kubisch R, et al. Among authors: roidl a. Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14. Int J Cancer. 2014. PMID: 24166050

7

The proto-oncogene KRAS is targeted by miR-200c.

Kopp F, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. Oncotarget. 2014 Jan 15;5(1):185-95. doi: 10.18632/oncotarget.1427. Oncotarget. 2014. PMID: 24368337 Free PMC article.

8

Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration.

Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. Mol Cancer. 2014 Jan 27;13:16. doi: 10.1186/1476-4598-13-16. Mol Cancer. 2014. PMID: 24468090 Free PMC article.

9

Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.

Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A. Kopp F, et al. Among authors: roidl a. Transl Oncol. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002. Transl Oncol. 2014. PMID: 25500079 Free PMC article.

10

Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.

Hermawan A, Wagner E, Roidl A. Hermawan A, et al. Among authors: roidl a. Oncol Rep. 2016 Mar;35(3):1732-40. doi: 10.3892/or.2015.4509. Epub 2015 Dec 22. Oncol Rep. 2016. PMID: 26708059

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters